Patents Examined by Raymond Henley, III
  • Patent number: 10196693
    Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: February 5, 2019
    Assignee: MEDIVATION PROSTATE THERAPEUTICS LLC
    Inventors: Amy Christian Peterson, Hirdesh Uppal
  • Patent number: 9974776
    Abstract: The invention provides a treatment of mesothelioma, especially malignant pleural mesothelioma, using an estrogen receptor ? subtype (ER?) agonist, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours; administering a platinum-containing anti-cancer drug to the patient. The invention also provides an ER? agonist and a platinum-containing anti-cancer drug for use in the treatment of mesothelioma in a patient, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours, administering the platinum-containing anti-cancer drug to the patient; and a kit comprising a platinum-containing anti-cancer drug and an ER? agonist.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 22, 2018
    Inventors: Stefan Nilsson, Laura Moro, Giulia Pinton, Arcangela Gabriella Manente
  • Patent number: 9943496
    Abstract: Nutritional supplement, feed formulation and methods to improve the efficiency of meat production of a bovine animal, using ethyl ferulate as a nutritional supplement; where the administration of ethyl ferulate at bovine animal, is premixed with an excipient food grade, feed formulation, balanced food, concentrated food, and the like. The ethyl ferulate administration is daily during the final stage of fattening bovine animal, wherein the final stage of fattening is 20 to 40 last days.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: April 17, 2018
    Assignee: LABORATORIOS MINKAB, S. A. DE C. V.
    Inventors: Jorge Selim Asaff Arancibia, Angel Emilio Aceves Diez, Humberto Gonzalez Rios, Rodrigo Nunes Pina
  • Patent number: 9907737
    Abstract: A composition which includes a) ferulic acid ethyl ester and b) one, two or more aryl alkanols. The combination of components a) and b) has an antimicrobial effect on products such as cosmetics.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: March 6, 2018
    Assignee: L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE
    Inventors: Wolfgang Beilfuss, Klaus Weber, Peter Oltmanns, Sabine Herweg, Sarah Erichsen, Carsten Bungenstock, Sonja Luthje
  • Patent number: 9867865
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 16, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 9861621
    Abstract: The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: January 9, 2018
    Assignee: Biomed Valley Discoveries, Inc.
    Inventors: Saurabh Saha, Linping Zhang, Xiaoyan Michelle Zhang
  • Patent number: 9861624
    Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteolytic bone metastases, with a dual inhibitor of MET and VEGF.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: January 9, 2018
    Assignee: Exelixis, Inc.
    Inventor: Dana T. Aftab
  • Patent number: 9849098
    Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 26, 2017
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama Mallampalli
  • Patent number: 9849134
    Abstract: A ?1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a ?1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the ?1-ADR agonist compound.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mehrdad Shamloo, Bitna Yi, Pooneh Memar Ardestani
  • Patent number: 9849103
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: December 26, 2017
    Inventor: Young Hee Ko
  • Patent number: 9833435
    Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: December 5, 2017
    Assignee: Blanchette Rockefeller Neurosciences Institute
    Inventor: Daniel L. Alkon
  • Patent number: 9814235
    Abstract: An amide compound represented by formula (I): [wherein A represents a 3- to 7-membered saturated heterocyclic ring which contains, as ring-forming component(s), one or more atoms or groups selected from the group consisting of an oxygen atom and —S(O)t—, t represents 0, etc., R1 and R2 are the same or different and represent a hydrogen atom, etc., n represents 0, etc., the following formula (II): represents a 5-membered aromatic ring, in which Z represents a nitrogen atom or a carbon atom and X1, X2 and X3 are the same or different and represent a nitrogen atom, etc., R3 and R4 are the same or different and represent a hydrogen atom, etc., m represents 0 to 2, Q represents one group selected from group A or a C1 to C8 chain hydrocarbon group optionally having one group selected from group A, Y represents an oxygen atom, etc., u represents 0, etc., and v represents 0, etc.] has excellent arthropod pest controlling effects.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: November 14, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Hiromasa Mitsudera, Kenichiro Awasaguchi, Tomotsugu Awano, Kazuya Ujihara
  • Patent number: 9814693
    Abstract: The present invention is directed to methods for treatment of malignancies in companion animals employing dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol, as well as analogs and derivatives thereof, in addition to a method to improve the efficacy and/or reduce the side effects of the administration of a therapeutic agent selected from the group consisting of dianhydrogalactitol, a derivative of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative of dibromodulcitol to a veterinary subject, the method comprising the steps of: (1 (identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the administration of the therapeutic agent to the veterinary subject; and (2) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the administration of the therapeutic agent to the veterinary subject.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: November 14, 2017
    Assignee: DELMAR PHARMACEUTICALS, INC.
    Inventors: Jeffrey A. Bacha, Dennis M. Brown, William J. Garner
  • Patent number: 9814714
    Abstract: The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: November 14, 2017
    Assignee: Plexxikon Inc.
    Inventors: Prabha N. Ibrahim, Chao Zhang, Wayne Spevak, Jiazhong Zhang, Guoxian Wu, Jack Lin, Hanna Cho, Marika Nespi, Songyuan Shi, Todd Ewing, Ying Zhang, Gideon Bollag
  • Patent number: 9814710
    Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: November 14, 2017
    Assignee: Euro-Celtique S.A.
    Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
  • Patent number: 9808428
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: November 7, 2017
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard E. Gendelman, Xin-Ming Liu
  • Patent number: 9801876
    Abstract: The present invention relates to a complex granule formulation comprising a first granular part comprising levocetirizine or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent; and a second granular part comprising montelukast or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent. This formulation can effectively inhibit the production of related compounds of levocetirizine and montelukast by allowing levocetirizine and montelukast to form clathrate complexes with cyclodextrin, and using an alkalinizing agent. This formulation not only shows increased stability and bioavailability, but also improves patient compliance owing to its effective masking of bitter taste.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 31, 2017
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Ho Taek Im, Taek Kwan Kwon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9795570
    Abstract: Methods and materials that can be used to regulate macrophage activation are described. Methods can utilize emodin to bi-directionally modulate macrophage activation and return macrophage phenotype to a homeostatic center (e.g., between M1 and M2 phenotypes) in various environmental settings. Methods can target multiple pathologies within a same individual. Methods can be utilized to inhibit macrophage phenotype activation and affect downstream response to phenotype inducing stimulus, thereby altering macrophage memory.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: October 24, 2017
    Assignee: University of South Carolina
    Inventor: Daping Fan
  • Patent number: 9795620
    Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 24, 2017
    Assignee: Dr. Reddy's Laboratories, Ltd.
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Supritha Vakada, Rajeev Singh Raghuvanshi
  • Patent number: 9789223
    Abstract: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: October 17, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David Knaack, John Winterbottom, David R. Kaes, Todd M. Boyce, Lawrence A. Shimp